These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 30054667)

  • 21. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model.
    Grauer OM; Sutmuller RP; van Maren W; Jacobs JF; Bennink E; Toonen LW; Nierkens S; Adema GJ
    Int J Cancer; 2008 Apr; 122(8):1794-802. PubMed ID: 18076066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas.
    Gousias K; von Ruecker A; Voulgari P; Simon M
    J Neuroimmunol; 2013 Nov; 264(1-2):84-90. PubMed ID: 24071056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model.
    Kim TG; Kim CH; Park JS; Park SD; Kim CK; Chung DS; Hong YK
    Clin Vaccine Immunol; 2010 Jan; 17(1):143-53. PubMed ID: 19889936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor CD8 T cell responses in glioma patients are effectively suppressed by T follicular regulatory cells.
    Lu L; Sun J; Su H; Luo S; Chen J; Qiu S; Chi Y; Lin J; Xu X; Zheng D
    Exp Cell Res; 2021 Oct; 407(2):112808. PubMed ID: 34508744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
    Berntsen A; Brimnes MK; thor Straten P; Svane IM
    J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
    Jordan M; Waxman DJ
    Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Galectin-1 and immunotherapy for brain cancer.
    Verschuere T; De Vleeschouwer S; Lefranc F; Kiss R; Van Gool SW
    Expert Rev Neurother; 2011 Apr; 11(4):533-43. PubMed ID: 21469926
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas.
    Pollack IF; Jakacki RI; Butterfield LH; Hamilton RL; Panigrahy A; Potter DM; Connelly AK; Dibridge SA; Whiteside TL; Okada H
    J Clin Oncol; 2014 Jul; 32(19):2050-8. PubMed ID: 24888813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
    Yamanaka R; Honma J; Tsuchiya N; Yajima N; Kobayashi T; Tanaka R
    J Neurooncol; 2005 Apr; 72(2):107-13. PubMed ID: 15925989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
    Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
    Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer.
    Saha A; Chatterjee SK
    Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.
    Ueda R; Fujita M; Zhu X; Sasaki K; Kastenhuber ER; Kohanbash G; McDonald HA; Harper J; Lonning S; Okada H
    Clin Cancer Res; 2009 Nov; 15(21):6551-9. PubMed ID: 19861464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma.
    Latha K; Yan J; Yang Y; Gressot LV; Kong LY; Manyam G; Ezhilarasan R; Wang Q; Sulman EP; Eric Davis R; Huang S; Fuller GN; Rao A; Heimberger AB; Li S; Rao G
    J Natl Cancer Inst; 2019 Mar; 111(3):292-300. PubMed ID: 29947810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of regulatory T cells in malignant glioma.
    Sonabend AM; Rolle CE; Lesniak MS
    Anticancer Res; 2008; 28(2B):1143-50. PubMed ID: 18505050
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
    Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
    Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of regulatory T lymphocytes in the induced immune response mediated by biological vaccines.
    López M; Aguilera R; Pérez C; Mendoza-Naranjo A; Pereda C; Ramirez M; Ferrada C; Aguillón JC; Salazar-Onfray F
    Immunobiology; 2006; 211(1-2):127-36. PubMed ID: 16446177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunotherapy for human glioma: innovative approaches and recent results.
    Hussain SF; Heimberger AB
    Expert Rev Anticancer Ther; 2005 Oct; 5(5):777-90. PubMed ID: 16221048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.